March 21, 2018 / 11:20 AM / 8 months ago

BRIEF-Akari Therapeutics Qtrly Loss Per Common Share $0.01

March 21 (Reuters) - Akari Therapeutics Plc:

* AKARI THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS RECENT CLINICAL PROGRESS

* AKARI THERAPEUTICS PLC - CAPSTONE, PHASE III NAÏVE PNH TRIAL EXPECTED TO OPEN IN Q1 2018

* AKARI THERAPEUTICS - BASED ON CURRENT CASH POSITION AND OPERATING PLAN, EXPECTS HAS SUFFICIENT CASH TO FUND OPERATIONS INTO Q2 2019

* AKARI THERAPEUTICS PLC - AS OF DECEMBER 31, 2017, COMPANY HAD CASH AND CASH EQUIVALENTS OF $28.1 MILLION

* AKARI THERAPEUTICS PLC - QTRLY LOSS PER COMMON SHARE $0.01 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below